Skip to main content

Advertisement

SpringerLink
Log in

Problems with GH doping in sports

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Human hGH is listed as a prohibited class E substance by the International Olympic Committee (IOC), and its use is considered as doping. However, until today the likelihood of being punished for using recombinant hGH is very limited: once injected, it is believed to be undetectable by laboratories. No official test is implemented in the doping control procedures, and the only situation when athletes were found guilty of doping with hGH arose from actions of customs officers or policemen arresting athletes carrying ampoules with them. The primary reason for the lack of an ac]test method is the amino acid sequence identity between the main fraction of pituitary derived hGH and recombinant hGH, which makes it difficult to discriminate between endogenous and exogenous hGH. In addition, hGH is known to have a very short half-life time in circulation of around 15 min. Recent efforts of endocrine researchers led to the identification of two main strategies promising to be useful for the detection of recombinant hGH application, which are reviewed in this article: on the one hand, changes in GH-dependent parameters after administration of recombinant GH have been shown to be possible indicators of GH abuse, because the increase in various parameters following recombinant hGH administration exceeds the variability commonly observed in normal, healthy subjects. More directly, another approach focuses on changes in the hGH isoform pattern in serum occurring after injection of recombinant hGH. Because of the negative feedback on pituitary hGH secretion, the relative abundance of isoforms other than 22 kD are greatly reduced after administration of recombinant hGH, which only consists of the 22 kD hGH isoform.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rickert VI, Pawlak-Morello C, Sheppard V, Jay MS. Human growth hormone: a new substance of abuse among ado-escents? Clin Pediatr (Phila) 1992, 31: 723–6.

    Article  CAS  Google Scholar 

  2. Wallace JD, Cuneo RC. Growth hormone and sport. Iternational Growth Monitor 2000, 10: 2–6.

    Google Scholar 

  3. Jorgensen JO, Vahl N, Hansen TB, Thuesen L, Hagen C, Christiansen JS. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol (Oxf) 1996, 45: 681–8.

    Article  CAS  Google Scholar 

  4. Gibney J, Wallace JD, Spinks T, et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999, 84: 2596–602.

    Article  PubMed  CAS  Google Scholar 

  5. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321: 1797–803.

    Article  PubMed  CAS  Google Scholar 

  6. Jorgensen JO, Thuesen L, Muller J, Ovesen P, Skakkebaek NE, Christiansen JS. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 1994, 130: 224–8.

    Article  PubMed  CAS  Google Scholar 

  7. Ezzat S, Fear S, Gaillard RC, et al. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2002, 87: 2725–33.

    Article  PubMed  CAS  Google Scholar 

  8. Crist DM, Peake GT, Egan PA, Waters DL. Body composition response to exogenous GH during training in highly conditioned adults. J Appl Physiol 1988, 65: 579–84.

    PubMed  CAS  Google Scholar 

  9. Crist DM, Peake GT, Loftfield RB, Kraner JC, Egan PA. Supplemental growth hormone alters body composition, muscle protein metabolism and serum lipids in fit adults: characterization of dose-dependent and response-recovery effects. Mech Ageing Dev 1991, 58: 191–205.

    Article  PubMed  CAS  Google Scholar 

  10. Deyssig R, Frisch H, Blum WF, Waldhor T. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol (Copenh) 1993, 128: 313–8.

    CAS  Google Scholar 

  11. Lange KH, Isaksson F, Juul A, Rasmussen MH, Bulow J, Kjaer M. Growth hormone enhances effects of endurance training on oxidative muscle metabolism in elderly women. Am J Physiol Endocrinol Metab 2000, 279: E989–96.

    PubMed  CAS  Google Scholar 

  12. Cuneo RC, Salomon F, Wiles CM, Sonksen PH. Skeleta muscle performance in adults with growth hormone deficiency. Horm Res 1990, 33: 55–60.

    Article  PubMed  Google Scholar 

  13. Cuneo RC, Salomon F, Wiles CM, et al. Histology of skeletal muscle in adults with GH deficiency: comparison with normal muscle and response to GH treatment. Horm Res 1992, 37: 23–8.

    Article  PubMed  CAS  Google Scholar 

  14. Sartorio A, Narici M, Conti A, Monzani M, Faglia G. Quadriceps and hand-grip strength in adults with childhood-onset growth hormone deficiency. Eur J Endocrino 1995, 132: 37–41.

    Article  CAS  Google Scholar 

  15. Janssen YJ, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999, 84: 279–84.

    PubMed  CAS  Google Scholar 

  16. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997, 82: 2877–84.

    PubMed  CAS  Google Scholar 

  17. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J App Physiol 1991, 70: 688–94.

    CAS  Google Scholar 

  18. Bottinelli R, Narici M, Pellegrino MA, et al. Contractile properties and fiber type distribution of quadriceps muscles in adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997, 82: 4133–8.

    Article  PubMed  CAS  Google Scholar 

  19. Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO, Bier DM. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 1992, 262: E261–7.

    PubMed  CAS  Google Scholar 

  20. Yarasheski KE, Zachweija JJ, Angelopoulos TJ, Bier DM. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol 1993, 74: 3073–6.

    PubMed  CAS  Google Scholar 

  21. Taaffe DR, Jin IH, Vu TH, Hoffman AR, Marcus R. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrino Metab 1996, 81: 421–5.

    CAS  Google Scholar 

  22. Frisch H. Growth hormone and body composition in athletes. J Endocrinol Invest 1999, 22: 106–9.

    PubMed  CAS  Google Scholar 

  23. Dean H. Does exogenous growth hormone improve athletic performance? Clin J Sport Med 2002, 12: 250–3.

    Article  PubMed  Google Scholar 

  24. Merola B, Longobardi S, Sofia M, et al. Lung volumes and respiratory muscle strength in adult patients with childhood- or adult-onset growth hormone deficiency: effect of 12 months’ growth hormone replacement therapy. Eur J Endocrinol 1996, 135: 553–8.

    Article  PubMed  CAS  Google Scholar 

  25. Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasburger CJ. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995, 80: 552–7.

    PubMed  CAS  Google Scholar 

  26. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physio 1991, 70: 695–700.

    CAS  Google Scholar 

  27. Hutler M, Schnabel D, Staab D, et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Med Sci Sports Exerc 2002, 34: 567–72.

    Article  PubMed  CAS  Google Scholar 

  28. Pichard C, Kyle U, Chevrolet JC, et al. Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study. Crit Care Med 1996, 24: 403–13.

    Article  PubMed  CAS  Google Scholar 

  29. Cittadini A, Cuocolo A, Merola B, et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 1994, 267: E219–25.

    PubMed  CAS  Google Scholar 

  30. Cuneo RC, Salomon F, Wilmshurst P, et al. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci (Colch) 1991, 81: 587–92.

    CAS  Google Scholar 

  31. Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993, 77: 790–3.

    PubMed  CAS  Google Scholar 

  32. Jorgensen JO, Moller J, Alberti KG, et al. Marked effects of sustained low growth hormone (GH) levels on day-today fuel metabolism: studies in GH-deficient patients and healthy untreated subjects. J Clin Endocrinol Metab 1993, 77: 1589–96.

    PubMed  CAS  Google Scholar 

  33. Christ ER, Cummings MH, Westwood NB, et al. The importance of growth hormone in the regulation of erythro-poiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metab 1997, 82: 2985–90.

    PubMed  CAS  Google Scholar 

  34. Ehrnborg C, Bengtsson BA, Rosen T. Growth hormone abuse. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14: 71–7.

    Article  PubMed  CAS  Google Scholar 

  35. Davies JS, Morgan CL, Currie CJ, Green JT. Growth hormone use by body builders. Br J Sports Med 1997, 31: 352–3.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  36. Healy ML, Russell-Jones D. Growth hormone and sport: abuse, potential benefits, and difficulties in detection. Br J Sports Med 1997, 31: 267–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  37. Kicman AT, Cowan DA. Peptide hormones and sport: misuse and detection. Br Med Bull 1992, 48: 496–517.

    PubMed  CAS  Google Scholar 

  38. White GL, Murdock RT, Richardson GE, Trunnell EP, Wilkins DG. Preventing growth hormone abuse: an emerging health concern. Health Educ 1989, 20: 4–7, 10.

    PubMed  CAS  Google Scholar 

  39. Council on Scientific Affairs. Drug abuse in athletes. Anabolic steroids and human growth hormone. JAMA 1988, 259: 1703–5.

    Article  Google Scholar 

  40. Macintyre JG. Growth hormone and athletes. Sports Med 1987, 4: 129–42.

    Article  PubMed  CAS  Google Scholar 

  41. Melmed S. Unwanted effects of growth hormone excess in the adult. J Pediatr Endocrinol Metab 1996, 9: 369–74.

    PubMed  Google Scholar 

  42. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000, 151: 551–7.

    Article  PubMed  CAS  Google Scholar 

  43. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000, 355: 610–3.

    Article  PubMed  CAS  Google Scholar 

  44. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrino Metab 2001, 86: 1868–70.

  45. Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. Lancet 2002, 360: 268–9.

    Article  PubMed  Google Scholar 

  46. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730–4.

    PubMed  CAS  Google Scholar 

  47. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-8.

  48. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279: 563–6.

    Article  PubMed  CAS  Google Scholar 

  49. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351: 1393–6.

    Article  PubMed  CAS  Google Scholar 

  50. Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J Natl Cancer Inst 2002, 94: 454–60.

    Article  PubMed  Google Scholar 

  51. Renehan AG, Bhaskar P, Painter JE, et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000, 85: 3417–24.

    Article  PubMed  CAS  Google Scholar 

  52. Swerdlow A, Higgins C, Adlard P, Preece M. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet 2002, 360: 273–7.

    Article  PubMed  CAS  Google Scholar 

  53. Pierard GE, Pierard-Franchimont C, Nikkels A, Nikkels-Tassoudji N, Arrese JE, Bourguignon JP. Naevocyte triggering by recombinant human growth hormone. J Pathol 1996, 180: 74–9.

    Article  PubMed  CAS  Google Scholar 

  54. Beuschlein F, Strasburger CJ, Siegerstetter V, et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med 2000, 342: 1871–6.

    Article  PubMed  CAS  Google Scholar 

  55. Abramson FP, Osborn BL, Teffera Y. Isotopic differences in human growth hormone preparations. Anal Chem 1996, 68:1971–2.

    Article  PubMed  CAS  Google Scholar 

  56. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000, 405: 635.

    Article  PubMed  CAS  Google Scholar 

  57. Holl RW, Schwarz U, Schauwecker P, Benz R, Veldhuis JD, Heinze E. Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. J Clin Endocrinol Metab 1993, 77: 216–20.

    PubMed  CAS  Google Scholar 

  58. Eliakim A, Brasel JA, Mohan S, Barstow TJ, Berman N, Cooper DM. Physical fitness, endurance training, and the growth hormone-insulin-like growth factor I system in adolescent females. J Clin Endocrinol Metab 1996, 81: 3986–92.

    PubMed  CAS  Google Scholar 

  59. Eliakim A, Scheett TP, Newcomb R, Mohan S, Cooper DM. Fitness, training, and the growth hormone-insulin-like growth factor I axis in prepubertal girls. J Clin Endocrinol Metab 2001, 86: 2797–802.

    PubMed  CAS  Google Scholar 

  60. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996, 98: 2612–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  61. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulinike growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995, 80: 2534–42.

    PubMed  CAS  Google Scholar 

  62. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-ike growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994, 41: 85–93.

    Article  CAS  Google Scholar 

  63. Bang P, Brandt J, Degerblad M, et al. Exercise-induced changes in insulin-like growth factors and their low molecular weight binding protein in healthy subjects and patients with growth hormone deficiency. Eur J Clin Invest 1990, 20: 285–92.

    Article  PubMed  CAS  Google Scholar 

  64. Hopkins NJ, Jakeman PM, Hughes SC, Holly JM. Changes in circulating insulin-like growth factor-binding protein-1 (IGFBP-1) during prolonged exercise: effect of carbohydrate feeding. J Clin Endocrinol Metab 1994, 79: 1887–90.

    PubMed  CAS  Google Scholar 

  65. Hornum M, Cooper DM, Brasel JA, Bueno A, Sietsema KE. Exercise-induced changes in circulating growth factors with cyclic variation in plasma estradiol in women. J App Physiol 1997, 82: 1946–51.

    CAS  Google Scholar 

  66. Poehlman ET, Rosen CJ, Copeland KC. The influence of endurance training on insulin-like growth factor-1 in older individuals. Metabolism 1994, 43: 1401–5.

    Article  PubMed  CAS  Google Scholar 

  67. Schwarz AJ, Brasel JA, Hintz RL, Mohan S, Cooper DM. Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J Clin Endocrinol Metab 1996, 81: 3492–7.

    PubMed  CAS  Google Scholar 

  68. Kraemer WJ, Aguilera BA, Terada M, et al. Responses of IGFI to endogenous increases in growth hormone after heavy-resistance exercise. J Appl Physiol 1995, 79: 1310–5.

    PubMed  CAS  Google Scholar 

  69. Kraemer WJ, Hakkinen K, Newton RU, et al. Effects of heavy-resistance training on hormonal response patterns in younger vs. older men. J Appl Physiol 1999, 87: 982–92.

    PubMed  CAS  Google Scholar 

  70. Leger J, Reverchon C, Porquet D, Noel M, Czernichow P. The wide variation in urinary excretion of human growth hormone in normal growing and growth hormone-deficient children limits its clinical usefulness. Horm Res 1995, 44: 57–63.

    Article  PubMed  CAS  Google Scholar 

  71. Flanagan DE, Taylor MC, Parfitt V, Mardell R, Wood PJ, Leatherdale BA. Urinary growth hormone following exercise to assess growth hormone production in adults. Clin Endocrinol (Oxf) 1997, 46: 425–9.

    Article  CAS  Google Scholar 

  72. Saugy M, Cardis C, Schweizer C, Veuthey JL, Rivier L. Detection of human growth hormone doping in urine: out of competition tests are necessary. J Chromatogr Biomed Appl. 1996, 687: 201–11.

    Article  CAS  Google Scholar 

  73. Wallace JD, Cuneo RC, Baxter R, et al. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab 1999, 84: 3591–601.

    PubMed  CAS  Google Scholar 

  74. Wallace JD, Cuneo RC, Lundberg PA, et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J Clin Endocrinol Metab 2000, 85: 124–33.

    PubMed  CAS  Google Scholar 

  75. Longobardi S, Keay N, Ehrnborg C, et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J Clin Endocrinol Metab 2000, 85: 1505–12.

    PubMed  CAS  Google Scholar 

  76. Kanaley JA, Weatherup-Dentes MM, Jaynes EB, Hartman ML. Obesity attenuates the growth hormone response to exercise. J Clin Endocrinol Metab 1999, 84: 3156–61.

    PubMed  CAS  Google Scholar 

  77. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997, 82: 550–5.

    PubMed  CAS  Google Scholar 

  78. Weiss S, Baumgart R, Jochum M, Strasburger CJ, Bidlingmaier M. Systemic regulation of distraction osteogenesis: a cascade of biochemical factors. J Bone Miner Res 2002, 17: 1280–9.

    Article  PubMed  CAS  Google Scholar 

  79. Baumann G. Growth hormone heterogeneity in human pituitary and plasma. Horm Res 1999, 51 (Suppl 1): 2–6.

    Article  PubMed  CAS  Google Scholar 

  80. Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hormone. Lancet 1999, 353: 895.

    Article  PubMed  CAS  Google Scholar 

  81. Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14: 99–109.

    Article  PubMed  CAS  Google Scholar 

  82. Jenkins P. Detection of doping. Lancet 1999, 353: 1532.

    Article  PubMed  CAS  Google Scholar 

  83. Wallace JD, Cuneo RC, Bidlingmaier M, et al. The response of molecular isoforms of growth hormone to acute exercise in trained adult males. J Clin Endocrinol Metab 2001, 86: 200–6.

    PubMed  CAS  Google Scholar 

  84. Wu Z, Bidlingmaier M, Strasburger CJ. Development of human growth hormone (hGH) isoform specific antibodies and their use in a possible test to detect hGH-doping in sports [abstract]. 84th Meeting of the Endocrine Society, San Francisco, 2002, P3–527.

    Google Scholar 

  85. Burget L, Wu Z, Bidlingmaier M, Strasburger CJ. Direct detection of human growth hormone (hGH) isoforms in serum by immunoprecipitation and western-blotting using specific antibodies: A possible test method to detect hGH-doping in sports [abstract]. 84th Meeting of the Endocrine Society, San Francisco, 2002, P2–116.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Unit, Medizinische Klinik — Innenstadt, Klinikum der Ludwig — Maximilians-University, Ziemssenstr. 1, 80336, Munich, Germany

    M. Bidlingmaier, Z. Wu & C. J. Strasburger

Authors
  1. M. Bidlingmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. J. Strasburger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bidlingmaier, M., Wu, Z. & Strasburger, C.J. Problems with GH doping in sports. J Endocrinol Invest 26, 924–931 (2003). https://doi.org/10.1007/BF03345245

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345245

Key-words

Search

Navigation